Cytokinetics (CYTK) Misses Q1 EPS by 2c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.67), $0.02 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $19.35 million versus the consensus estimate of $8.59 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
- Goldman Sachs Upgrades Tingyi Cayman Islands Holding Corp. (322:HK) (TCYMY) to Buy
- JPMorgan Reiterates Underweight Rating on Hapag-Lloyd AG (HLAG:GR) (HLAGF)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
